CN111249274B - Application of ginkgolide B in preparation of glioma cell activity inhibitor - Google Patents
Application of ginkgolide B in preparation of glioma cell activity inhibitor Download PDFInfo
- Publication number
- CN111249274B CN111249274B CN201911013105.XA CN201911013105A CN111249274B CN 111249274 B CN111249274 B CN 111249274B CN 201911013105 A CN201911013105 A CN 201911013105A CN 111249274 B CN111249274 B CN 111249274B
- Authority
- CN
- China
- Prior art keywords
- glioma
- ginkgolide
- cell
- cells
- glioma cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010018338 Glioma Diseases 0.000 title claims abstract description 82
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 71
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 title claims abstract description 64
- 230000000694 effects Effects 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000003112 inhibitor Substances 0.000 title claims abstract description 16
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 title abstract 6
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 13
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract description 12
- 208000029824 high grade glioma Diseases 0.000 claims abstract description 11
- 201000011614 malignant glioma Diseases 0.000 claims abstract description 11
- 201000007983 brain glioma Diseases 0.000 claims abstract description 7
- 230000003211 malignant effect Effects 0.000 claims abstract description 7
- SQOJOAFXDQDRGF-ZMVGXLHTSA-N ginkgolide b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-ZMVGXLHTSA-N 0.000 claims description 72
- 229930063422 Bilobalide A Natural products 0.000 claims description 15
- 230000037396 body weight Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 230000035755 proliferation Effects 0.000 abstract description 11
- 230000005012 migration Effects 0.000 abstract description 6
- 238000013508 migration Methods 0.000 abstract description 6
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 230000022131 cell cycle Effects 0.000 abstract description 3
- 230000002503 metabolic effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 74
- 229940079593 drug Drugs 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 238000002372 labelling Methods 0.000 description 6
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 5
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 3
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000030769 platelet activating factor receptor Human genes 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229930009674 sesquiterpene lactone Natural products 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- -1 diterpene lactone Chemical class 0.000 description 2
- 230000000214 effect on organisms Effects 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 229930184727 ginkgolide Natural products 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- KWWLGXNRLABSMP-UHFFFAOYSA-N phosphoric acid;2,3,5,6-tetramethylpyrazine Chemical compound OP(O)(O)=O.CC1=NC(C)=C(C)N=C1C KWWLGXNRLABSMP-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229940123251 Platelet activating factor antagonist Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000007444 cell Immobilization Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of biological medicine, aims at the problem that ginkgolide B in the prior art does not have an anti-cancer effect on malignant glioma, and discloses an application of ginkgolide B in preparation of a glioma cell activity inhibitor, wherein the glioma cell activity inhibitor comprises ginkgolide B and derivatives thereof; the glioma cells comprise one or more of glioma cell U-87MG, glioma cell U-251MG, or glioma cell A172; the glioma cell activity inhibitor is applied to a malignant brain glioma chemotherapy drug. The invention discovers that the ginkgolide B has a certain treatment effect on the malignant glioma; the ginkgolide B can inhibit the migration and proliferation of glioma cells, reduce the activity of ATP enzyme so as to influence the metabolic level of glioma cells, block the cell cycle and induce apoptosis, and provides a new alternative scheme of chemotherapeutic drugs for treating malignant glioma.
Description
Technical Field
The invention relates to the field of biological medicines, in particular to application of ginkgolide B in preparation of a glioma cell activity inhibitor.
Background
Glioblastomas (GBMs) are the most malignant of the central nervous system tumors, with a survival rate of less than 10% for more than five years in patients. Glioma grows and is characterized by invasive growth, and has no obvious boundary with normal brain tissue, so theoretically, the glioma cannot be completely excised by operation, and still has the problems of difficult treatment, poor postoperative prognosis and the like. Despite the progress of therapeutic approaches to glioblastoma over the last decade, chemotherapy is still the most mature method of treating the disease at present. However, in terms of current clinical application, the traditional chemotherapeutic drugs have the problems of great side effect, tumor drug resistance, incapability of penetrating blood brain barrier and the like. Therefore, a small molecular drug with stronger effect and less toxic and side effect on normal cells is urgently needed to treat the malignant glioma.
In recent years, biologists have studied a large number of mixtures extracted from herbs as a new source of anticancer drugs, and several natural products have been demonstrated to have significant anticancer effects against various cancers, such as leukemia, cervical cancer, ovarian cancer. The ginkgolide compound belongs to a terpenoid, consists of sesquiterpene lactone and diterpene lactone, and is an important active ingredient in ginkgo leaves. Bilobalide belongs to sesquiterpene lactone, and is the only sesquiterpene lactone compound found in ginkgo leaves at present. The ginkgolide B (BN52021) has the strongest activity and physiological activity in ginkgolide, is the strongest platelet activating factor antagonist discovered so far, can be clinically used for treating thrombus, acute pancreatitis and cardiovascular diseases, can also be used for treating metastatic cancer, has a protective effect on damaged neurons, and also has the effects of resisting oxidation and delaying aging.
The patent number CN200510109596.X is 'a pharmaceutical composition containing ginkgolide B and a preparation method and application thereof', and particularly discloses a pharmaceutical composition containing ginkgolide B, which comprises ligustrazine phosphate and ginkgolide B, wherein the weight of the ligustrazine phosphate in the pharmaceutical composition is 10-500 times that of the ginkgolide B, and the preparation method of the pharmaceutical composition.
The ginkgolide B has a certain treatment effect on metastatic cancers as a long-term medicament for treating cardiovascular and cerebrovascular diseases, but the anticancer effect of the ginkgolide B on malignant glioma is not reported in the medicament research at present.
Disclosure of Invention
The invention is in order to overcome the problem that ginkgolide B of the prior art does not have its anticancer effect on malignant glioma yet, disclose the application of ginkgolide B in preparing glioma cell activity inhibitor, find that ginkgolide B can be regarded as an active substance through the study, have certain therapeutic action on malignant glioma, the natural product, almost non-toxic, the minus effect is very little; the ginkgolide B can inhibit the migration and proliferation of glioma cells to different degrees, and can also reduce the activity of ATP enzyme so as to influence the metabolic level, block the cell cycle and induce apoptosis, thereby providing a new alternative scheme of chemotherapeutic drugs for the treatment of malignant glioma.
In order to achieve the purpose, the invention adopts the following technical scheme:
application of bilobalide B and its derivatives in preparing glioma cell activity inhibitor is provided.
A glioma cell activity inhibitor comprises bilobalide B and derivatives thereof, wherein the bilobalide B has a specific structural formula as follows:
preferably, the glioma cells comprise one or more of glioma cell U-87MG, glioma cell U-251MG, or glioma cell A172.
The glioma cell activity inhibitor is applied to a malignant brain glioma chemotherapy drug.
With respect to the molecular mechanism of action of ginkgolide B on glioma, studies have been made to show that ginkgolide B is the strongest antagonist of Platelet Activating Factor (PAF) found so far, and data have been made to show that Platelet Activating Factor Receptor (PAFR) is specifically highly expressed in glioma, and thus ginkgolide B is highly likely to act on glioma by inhibiting PAFR. In addition, ginkgolide B can also inhibit the progression of glioma by changing Ras/MAPK signal to induce cell differentiation.
Preferably, the chemotherapeutic agent comprises bilobalide B and one or more of the pharmaceutically acceptable esters of bilobalide B.
Preferably, the administration concentration of ginkgolide B to glioma cell A172 is 1095-1100. mu.M, the administration concentration to glioma cell U-87MG is 1085-1090. mu.M, and the administration concentration to glioma cell U-251MG is 995-1000. mu.M.
Preferably, the chemotherapeutic agent comprises an inhibitor of ginkgolide B and a pharmaceutically acceptable carrier and/or excipient.
Preferably, the malignant brain glioma chemotherapeutic drug of the chemotherapeutic drug is an oral preparation or an injection preparation.
Preferably, the oral preparation is in the form of a capsule or a tablet.
Preferably, the dosage of the oral formulation is about 5-5.2mg/kg body weight, more preferably 5mg/kg body weight.
Therefore, the invention has the following beneficial effects:
(1) researches show that the ginkgolide B can be used as an active substance, has a good treatment effect on malignant glioma, is a natural product and is almost nontoxic;
(2) the ginkgolide B can obviously inhibit the migration and proliferation of glioma cells, strictly control the proliferation rate of the glioma cells and have small side effect on organisms;
(3) but also can reduce the activity of ATP enzyme to influence the metabolic level, block the cell cycle and induce apoptosis, and inhibit the formation of glioma cells from the source, so the preparation method has excellent treatment effect;
(4) provides a new alternative scheme of chemotherapeutic drugs for the treatment of malignant brain glioma and enriches the types of inhibiting drugs for malignant brain glioma.
Drawings
FIG. 1 is a graph showing the dose-effect relationship between ginkgolide B and the inhibition of cell proliferation in three glioma cell lines.
FIG. 2 is a graph showing the growth of U-87MG cells under the action of ginkgolide B.
FIG. 3 is a light microscope photograph of growth inhibition and cell morphology change of three glioma cell lines with different concentrations of ginkgolide B.
FIG. 4 is a statistical graph of the effect of ginkgolide B on cell migration distance of three glioma cells.
FIG. 5 is a bar graph (5(B)) showing the results of BrdU labeling for quantifying the effect of ginkgolide B on glioma cell proliferation (5 (a)).
FIG. 6 is a histogram (6(a)) and a statistical bar chart (6(B)) showing the effect of ginkgolide B on the growth of intracranial glioma in C57B6 mice.
Detailed Description
The invention is further described with reference to specific embodiments.
Examples
I. Effect of ginkgolide B on proliferation and toxicity of glioma cells U-87MG
Glioma cells U-87MG (purchased from ATCC) were prepared in DMEM medium containing 10% fetal bovine serum and added to a 96-well plate at 100. mu.l per well (5000 cells/well). The plates were pre-incubated in an incubator for 24 hours (37 ℃, 5% CO)2). DMEM medium containing 10% fetal bovine serum at final concentrations of 0. mu.M, 250. mu.M, 500. mu.M, 1000. mu.M, 2000. mu.M ginkgolide B was added to wells of the plate, 200. mu.l per well, respectively. The plates were incubated in an incubator for 48 hours. The medium was discarded and replaced with DMEM medium containing 10% CCK 8. The plates were incubated in an incubator for 1 hour. The absorbance (OD value) at 450nm was measured with a microplate reader. Culture wells without glioma cells U-87MG and ginkgolide B and containing CCK8 were used as blank controls, and culture wells without ginkgolide B and containing glioma cells U-87MG and CCK8 were used as negative controls.
And (3) activity calculation: cell viability [ (%) [ a (medicated) -a (blank) ]/[ a (0 medicated) -a (blank) ] × 100
A (dosing): absorbance of wells containing glioma cells U-87MG, CCK8 and bilobalide B
A (blank): absorbance of wells with media and CCK8 without glioma cells U-87MG and bilobalide B
A (0 dosing): absorbance of wells with glioma cells U-87MG, CCK8 and no bilobalide B
Cell viability: cell proliferation Activity or cytotoxic Activity
Under the same conditions, the test was carried out using glioma cell lines A172 and U-251MG instead of U-87MG, and the results are shown in FIG. 1, wherein the half-inhibitory concentrations of ginkgolide B on glioma cell lines A172, U-87MG and U-251MG were 1098. mu.M, 1087. mu.M and 996. mu.M, respectively.
II. Inhibition of proliferation of different glioma cells by ginkgolide B
Mu.l of glioma cells U-87MG (5000 per well) were plated in 96-well plates in DMEM medium containing 10% fetal bovine serum. The plates were pre-incubated in an incubator for 24 hours (37 ℃, 5% CO)2). DMEM medium containing 10% fetal bovine serum containing 0.5. mu.M ginkgolide B was added to the plates at 200. mu.l per well, and DMEM medium containing 10% fetal bovine serum containing an equivalent amount of PBS instead of ginkgolide B was used as a control. The plates were incubated in an incubator for an appropriate period of time (0-6 days), and the cells in the plates with and without drug added were counted and growth curves were plotted daily at fixed times.
Under the same conditions, glioma cell lines A172 and U-251MG were used instead of U-87MG respectively, and the results are shown in FIG. 2, wherein the number of cells without drug treatment is normally increased, while the proliferation speed of cells treated by ginkgolide B is extremely slow, and apoptosis occurs under high concentration of drug.
III Effect of Bilobalide B on glioma migration Capacity
1. Preparation of cell samples
A-172MG cells growing logarithmically are spread in a six-well plate, when the confluence degree of the cells reaches about 80%, a scratching experiment is carried out by using a medium-sized gun head, the cells floating are washed for 2 times by PBS, and serum-free DMEM culture media respectively containing medium-concentration (1000 mu M) and low-concentration (500 mu M) ginkgolide B and ginkgolide B are added.
2. Photographing observation
The scratch part was photographed every 24 hours under a microscope, and the scratch width was statistically analyzed.
Under the same conditions, the results of the experiment using U251 cells instead of A-172MG cells are shown in FIG. 4, and the statistical results are shown in FIG. 4 d, which shows that the migration ability of A-172MG cells treated with ginkgolide B is significantly reduced compared with that of non-drug-treated cells.
IIII and BrdU labeling method for analyzing influence of ginkgolide B on cell proliferation
1. Preparation of cell samples:
taking logarithmic growth U-87MG cells, culturing until the confluence degree is 70%, adding ginkgolide B with final concentration of 500 μ M and 1000 μ M, and culturing for 48 h.
2. BrdU labeling:
a.48 hours later BrdU (5-bromodeoxyuridine) was added at a final concentration of 90g/L and incubated at 37 ℃ for 2 hours.
B. After 2 hours incubation, the medium was discarded and the cells were washed 2 times with PBS for 5 minutes each.
3. Cell immobilization:
mu.l of cell fixative (4% paraformaldehyde) was added to each well and incubated at room temperature for 30 minutes, the fixative was discarded and washed 3 times with PBS for 5 minutes each.
4. HCl fixation:
adding 2M HCl aqueous solution to each well of the culture wells in the step 3, incubating the wells in an environment at 37 ℃ for 20 minutes, washing the wells with PBS for 2 times, adding 0.1M boric acid buffer solution to each well at pH8.5 to cover the cells, incubating the wells for 10 minutes, and washing the wells with PBS for 3 times.
5. And (3) sealing:
blocking with 5% sheep serum for 1 hour at room temperature.
6. Incubation of primary antibody and secondary antibody
After primary antibody (mouse BrdU monoclonal antibody) was incubated overnight at 4 ℃ and washed 3 times with PBS, secondary antibody (coat-anti-mouse IgG1(r1),594) was incubated for 1 hour, DAPI (4', 6-diamidino-2-phenylindole) was added 5 minutes before the end of the secondary antibody incubation in a volume ratio of 1:10000, and PBS was washed three times. Pictures were taken under a fluorescent microscope.
Under the same conditions, the results of the experiment using A172 cells instead of U-87MG cells are shown in FIG. 5, and the statistical results in FIG. 5B show that the proliferation degree of the U-87MG cells treated with ginkgolide B is significantly reduced compared with the cells not treated with drug.
7. Animal experiments
Intracranial transplantation of 5X 10C 57B6 mice at 3-4 weeks4~1×105The GL261 cells of (a) in (b),brain glioma was formed in about 2 weeks, and bilobalide B drug-treated group (oral gavage) and control group were established, with the results shown in fig. 6: the oral administration of 5mg/kg body weight of ginkgolide B was effective in inhibiting the growth of intracranial glioma, and the statistical results are shown in B of FIG. 6.
The proliferation curves in fig. 1, the cell activities of the three tumor cell lines and the control normal glial cells at different concentrations of ginkgolide B, and from this, the semi-lethal dose of different ginkgolide B on the cell lines was calculated; FIG. 2 shows the growth curve (U87) of glioma cells U87 with varying concentrations of ginkgolide B over time, showing that treatment with ginkgolide B at a semilethal concentration completely inhibited the growth of glioma cells, whereas treatment with ginkgolide B at a semilethal concentration 1/2 also partially inhibited the growth of glioma cells; FIG. 3 is a cell morphology observation, and the growth inhibition and the cell morphology change of the three glioma cell lines are realized by the ginkgolide B with different concentrations, so that the number of the cells is reduced and the cell morphology is shrunk and rounded or even floated under the action of the ginkgolide B; FIG. 4 shows cell migration, which is significantly inhibited by increasing ginkgolide B concentration. Under the treatment of high-concentration ginkgolide B, the healing of cell scratches becomes slow; FIG. 5 shows the effect of BrdU labeling on glioma cell proliferation of ginkgolide B, and the effect of Ki-67 labeling on non-resting state Brdu labeling on proliferative cells, which shows that both non-resting state and proliferative glioma cells are inhibited under treatment of ginkgolide B, and the corresponding quantitative results are shown in the bar chart of FIG. 5 (B). Meanwhile, as shown in fig. 6, it can be seen through animal experimental studies that the bilobalide B inhibits the growth of glioma cells not only effectively in vitro but also well in vivo formed glioma, and the corresponding quantitative results are shown in the histogram of fig. 6 (B).
Therefore, the ginkgolide B serving as an active substance has a good treatment effect on malignant glioma, is a natural product, can inhibit the migration and proliferation of glioma cells to different degrees, strictly controls the proliferation rate of the glioma cells, and has small side effect on organisms.
From the data associated with the above examples, it can be seen that the above requirements can be satisfied in all aspects only by the embodiments within the scope of the claims of the present invention, and that an optimized embodiment can be obtained, and that an inhibitor of the activity of a glioma cell containing bilobalide B with the optimum activity can be obtained. The change of the mixture ratio, the replacement/addition/subtraction of raw materials or the change of the feeding sequence can bring corresponding negative effects.
The raw materials and equipment used in the invention are common raw materials and equipment in the field if not specified; the methods used in the present invention are conventional in the art unless otherwise specified.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and all simple modifications, alterations and equivalents of the above embodiments according to the technical spirit of the present invention are still within the protection scope of the technical solution of the present invention.
Claims (3)
1. The application of bilobalide B as the only active component in preparing glioma cell activity inhibitor;
the glioma cells comprise one or more of glioma cell U-87MG, glioma cell U-251MG, or glioma cell A172.
3. use of the glioma cell activity inhibitor of claim 1 in the preparation of a chemotherapeutic drug for malignant brain glioma;
the administration concentration of the ginkgolide B to the glioma cell A172 is 1095-;
the chemotherapeutic drug comprises an inhibitor of ginkgolide B and a pharmaceutically acceptable carrier and/or excipient;
the malignant glioma chemotherapeutic drug of the chemotherapeutic drug is an oral preparation or an injection preparation;
the dosage form of the oral preparation is capsules or tablets;
the dosage of the oral preparation is 5-5.2mg/kg body weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911013105.XA CN111249274B (en) | 2019-10-23 | 2019-10-23 | Application of ginkgolide B in preparation of glioma cell activity inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911013105.XA CN111249274B (en) | 2019-10-23 | 2019-10-23 | Application of ginkgolide B in preparation of glioma cell activity inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111249274A CN111249274A (en) | 2020-06-09 |
CN111249274B true CN111249274B (en) | 2022-04-01 |
Family
ID=70943814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911013105.XA Active CN111249274B (en) | 2019-10-23 | 2019-10-23 | Application of ginkgolide B in preparation of glioma cell activity inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111249274B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116251095A (en) * | 2023-04-21 | 2023-06-13 | 南京力诚生物医药科技有限公司 | Application of bilobalide B in preparing medicine for preventing tumor metastasis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090099102A1 (en) * | 2005-10-27 | 2009-04-16 | The Brigham And Women's Hospital, Inc. | Ginkgolides in the Treatment and Prevention of Ovarian Cancer |
CN103483351B (en) * | 2013-10-11 | 2016-06-29 | 湖北诺克特药业股份有限公司 | The extracting method of a kind of bilobalide and application |
-
2019
- 2019-10-23 CN CN201911013105.XA patent/CN111249274B/en active Active
Non-Patent Citations (3)
Title |
---|
IL-6对人脑胶质瘤细胞侵袭性的影响及相关机制研究;李蓉晖;《中国博士学位论文全文数据库 医药卫生科技辑》;20101015;E072-146 * |
彭珊瑛等.银杏内酯B对星形胶质细胞释放NO、IL-6及趋化因子RANTES的影响.《药学学报》.2010,第45卷(第9期),第1103-1108页. * |
银杏内酯B对星形胶质细胞释放NO、IL-6及趋化因子RANTES的影响;彭珊瑛等;《药学学报》;20101231;第45卷(第9期);第1103-1108页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111249274A (en) | 2020-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW386877B (en) | Antitumour compositions containing taxane derivatives | |
DE60117615T2 (en) | MEDICINAL COMBINATIONS (FOR EXAMPLE CHLOROPROMAZINE AND PENTAAMIDINE) FOR THE THERAPY OF NEOPLASTIC DISEASES | |
CN108159038A (en) | A kind of pharmaceutical composition and its purposes in the drug for preparing treatment multi-drug resistance of the tumor | |
CN102065865A (en) | Multiple myeloma treatments | |
CN111558044B (en) | Pharmaceutical composition containing sunitinib, and preparation and application thereof | |
CN106466315B (en) | Use of butylene phthalide | |
CN111249274B (en) | Application of ginkgolide B in preparation of glioma cell activity inhibitor | |
CN100522184C (en) | Extract with anti-tumor and anti-poisonous activity | |
CN101511351A (en) | Combination methods of treating cancer | |
CN109620836B (en) | Compound pharmaceutical composition with breast cancer resistance, application thereof and medicine based on composition | |
JP7307732B2 (en) | Use of ginsenoside M1 for the manufacture of a medicament for treating oral cancer | |
CN109528731B (en) | Pharmaceutical composition with synergistic effect for treating multiple myeloma and application thereof | |
CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
CN109793727A (en) | A kind of pharmaceutical composition and its application of effective anti-malignant tumor | |
CN105663147B (en) | Application of 4-hydroxy salicylanilide in preparation of antitumor drugs | |
WO2021023291A1 (en) | Use of proflavine in treatment of lung cancers | |
CN108853506A (en) | A kind of combination drug and application thereof for treating leukaemia | |
CN108451905B (en) | Gambogic acid nanoemulsion preparation and preparation method and application thereof | |
EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
KR102637904B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising 3-ketoacyl CoA thiolase inhibitor and Carnitine Acylcarnitine Carrier inhibitor | |
CN111773377A (en) | Application of anidulafungin in preparation of antitumor drugs and antitumor drugs | |
CN110215460B (en) | Combined drug for resisting tumors | |
CN114288303B (en) | Antineoplastic pharmaceutical composition containing piperazines and application thereof | |
CN111655252A (en) | Composition containing ferrous amino acid particles and application thereof in preparing medicine for treating or improving pancreas-related diseases | |
CN113384590B (en) | Application of quercus acutissima acid in preparation of medicine for treating pancreatic cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |